Arrowhead Pharmaceuticals (MEX:ARWR) NonCurrent Deferred Liabilities: MXN877 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ARWR Arrowhead Pharmaceuticals Inc MEX:ARWR
53 GF Score
Price MXN454.55
GF Value MXN319.36
! 4 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals NonCurrent Deferred Liabilities?

Arrowhead Pharmaceuticals MEX:ARWR 53 NonCurrent Deferred Liabilities is MXN877 Mil as of Mar. 2026. GuruFocus rates MEX:ARWR with a GF Score™ of 53/100 and a GF Value™ of MXN319.36. The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Arrowhead Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Mar. 2026 was MXN877 Mil.

Arrowhead Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Arrowhead Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals NonCurrent Deferred Liabilities Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,703.80 1,125.43 0.00 0.00 0.00

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 969.16 876.66
MEX:ARWR
53GF Score
Arrowhead Pharmaceuticals Inc MEX:ARWR
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of MXN877 Mil mean?
Arrowhead Pharmaceuticals (MEX:ARWR) has a NonCurrent Deferred Liabilities of MXN877 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' NonCurrent Deferred Liabilities too high?
Arrowhead Pharmaceuticals' current NonCurrent Deferred Liabilities is MXN877 Mil. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' NonCurrent Deferred Liabilities compare to CYTK and TECH?
Arrowhead Pharmaceuticals' NonCurrent Deferred Liabilities of MXN877 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current NonCurrent Deferred Liabilities is MXN877 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current NonCurrent Deferred Liabilities of MXN877 Mil. The stock's GF Value™ is MXN319.36, compared to a current price of MXN454.55 — trading 42.3% above its estimated fair value. The current NonCurrent Deferred Liabilities is MXN877 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current NonCurrent Deferred Liabilities is MXN877 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of MXN454.55 is trading 42.3% above its estimated GF Value™ of MXN319.36.

Key valuation signals for MEX:ARWR:

  • NonCurrent Deferred Liabilities: MXN877 Mil
  • GF Value™: MXN319.36 vs. price of MXN454.55 (42.3% above fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
53GF Score

Get the complete analysis for MEX:ARWR

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN454.55
Price
MXN319.36
GF Value